Market Research Logo

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015’, provides an overview of the Retinitis Pigmentosa (Retinitis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Retinitis Pigmentosa (Retinitis) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Retinitis Pigmentosa (Retinitis) Overview
Therapeutics Development
Pipeline Products for Retinitis Pigmentosa (Retinitis) - Overview
Pipeline Products for Retinitis Pigmentosa (Retinitis) - Comparative Analysis
Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies
Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes
Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Retinitis Pigmentosa (Retinitis) - Products under Development by Companies
Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
Acucela Inc.
Amarantus Bioscience Holdings, Inc.
Applied Genetic Technologies Corporation
Asklepios BioPharmaceutical, Inc.
BioDiem Ltd
Caladrius Biosciences, Inc.
DNAVEC Corporation
Dompe Farmaceutici S.p.A.
Genable Technologies Limited
GenSight Biologics SA
Grupo Ferrer Internacional, S.A.
International Stem Cell Corporation
Isis Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals Inc.
Neurotech Pharmaceuticals, Inc.
Ocata Therapeutics, Inc.
Orphagen Pharmaceuticals, Inc.
QLT Inc.
R-Tech Ueno, Ltd.
ReNeuron Group Plc
Sanofi
Shire Plc
Spark Therapeutics, Inc.
Sun Pharma Advanced Research Company Ltd.
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMRS-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibodies to Antagonize IL-6 for Retinitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BDM-E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BNP-RP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ECL-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emixustat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FIB-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Ocular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Ophthalmology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GT-038 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISISRHO-2.5Rx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KIRA-6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NT-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OCU-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRO-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
proinsulin human SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QLT-091001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Nerve Growth Factor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ReN-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinal Progenitor Cells for Ophthalmological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGX-321 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RST-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-421869 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHP-630 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPK-RPE-65 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Age Related Macular Degeneration and Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy to Activate MFRP for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
unoprostone isopropyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinitis Pigmentosa (Retinitis) - Recent Pipeline Updates
Retinitis Pigmentosa (Retinitis) - Dormant Projects
Retinitis Pigmentosa (Retinitis) - Discontinued Products
Retinitis Pigmentosa (Retinitis) - Product Development Milestones
Featured News & Press Releases
May 14, 2015: Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 08, 2015: Presentations of two studies on Unoprostone (development code UF-021) for retinitis pigmentosa announced at The Association for Research in Vision and Ophthalmology 2015
May 07, 2015: Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 05, 2015: Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
Apr 29, 2015: Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
Apr 09, 2015: Neostem Announces Extension Of Study Under Grant From California Institute Of Regenerative Medicine To Fund Research Of Retinal Disease
Mar 09, 2015: The end of a Phase 3 Clinical Study and Preliminary Findings from a Phase 3 of Unoprostone for treatment of Retinitis Pigmentosa
Feb 02, 2015: OptiKira, a New Biotech Start-up, Created to Develop Drugs to Prevent Cell Death Caused by the Unfolded Protein Response
Jan 12, 2015: RetroSense Therapeutics to Present at 7th Annual Biotech Showcase Conference
Dec 23, 2014: Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2015
Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corporation, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by BioDiem Ltd, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences, Inc. , H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by DNAVEC Corporation, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici S.p.A., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Genable Technologies Limited, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by International Stem Cell Corporation, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Ocata Therapeutics, Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by QLT Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by R-Tech Ueno, Ltd., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics, Inc., H1 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Retinitis Pigmentosa (Retinitis) Therapeutics - Recent Pipeline Updates, H1 2015
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2015
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2015
Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report